Korean Tobacco Reports Increase in Q2 Earnings

Aug.31.2022
Korean Tobacco Reports Increase in Q2 Earnings
KT&G's Q2 revenue rose 10.9%, boosted by overseas sales growth and higher real estate profits. Traditional cigarette sales also increased.

The latest financial report released by Korean Tobacco shows that their Q2 2022 revenue was KRW 1.42 trillion (approximately RMB 0.0052 per Korean won), a growth of 10.9% compared to the same period last year. The comprehensive operating profit was KRW 327.6 billion, an increase of 1% compared to the same period last year. Net profit reached KRW 330.1 billion, a year-on-year increase of 34%.


The company reported an increase in overall revenue, attributed to growth in overseas market sales and an improvement in real estate profit margins. The company's traditional cigarette business saw growth, benefiting from emerging markets such as South America and improved sales in Indonesia. Additionally, the company's heated tobacco product increased its market share in the domestic market from 40.4% in 2021 to 47% in 2022.


Currently, heated tobacco products account for 16.7% of all tobacco sales in South Korea. The company predicts that despite rising interest rates and soaring commodity prices, their traditional cigarette and electronic cigarette businesses will continue to grow in the coming months.


Statement


This article is compiled from third-party information and is intended for industry-related communication and learning purposes.


This article does not represent the views of 2FIRSTS and we are unable to confirm the authenticity and accuracy of its contents. The translation of this article is solely intended for industry communication and research purposes.


Due to limitations in translation abilities, the translated article may not fully reflect the original text. Please refer to the original text for accuracy.


2FIRSTS maintains complete alignment with the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and positions.


The copyright for compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Oklahoma DOC to allow inmates to buy nicotine vapes and pouches in 2026
Oklahoma DOC to allow inmates to buy nicotine vapes and pouches in 2026
Oklahoma’s Department of Corrections says it will begin allowing inmates to buy single-use nicotine vapes and nicotine pouches through prison canteens in 2026, framing the move as a strategy to reduce contraband-driven debts and prison violence. Officials say inmates will be barred from using personal nicotine products, the devices will be disposable and non-cartridge-based, and the program will be self-funded through inmate purchases rather than taxpayer money.
Feb.05 by 2FIRSTS.ai
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
West Virginia Senate Backs Vape Tax Increase to Offset Income Tax Cut
The West Virginia Senate approved a 10% personal income tax cut on February 22, 2026, with part of the revenue offset coming from increased excise taxes on vape and e-cigarette products.
News
Feb.23
Product | OXBAR Lists GOSLIM Disposable Vape on Its Website, Featuring Embedded Leather and a Slim Display Window Design
Product | OXBAR Lists GOSLIM Disposable Vape on Its Website, Featuring Embedded Leather and a Slim Display Window Design
OXBAR has updated its official website and listed a new disposable product, GOSLIM. The device is rated at 26,000 puffs, measures 40 × 22 × 110 mm, and weighs about 75 g, featuring an “embedded leather” exterior design. It supports two power modes—ECO and BOOST—and includes a digital display showing remaining battery percentage, remaining e-liquid level, and the active mode.
Jan.21 by 2FIRSTS.ai
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Stresses “Predictability” as Science Chief Addresses Industry Uncertainty
FDA Commissioner Marty Makary briefly appeared at the February 10 PMTA roundtable, underscoring the importance of regulatory predictability. At the close of the session, Office of Science Director Matthew Farrelly responded to industry concerns over review uncertainty, stating the agency will issue a written summary of feedback, while reiterating that no fixed quantitative risk benchmark governs authorization decisions.
Feb.11
Azerbaijan moves to fine and confiscate e-cigarettes across supply chain; full ban expected April 1, 2026
Azerbaijan moves to fine and confiscate e-cigarettes across supply chain; full ban expected April 1, 2026
Azerbaijan is considering administrative penalties for the use, import, export, production, wholesale and retail sale, and storage for sale of e-cigarettes, including confiscation of products. The proposed amendments were discussed at a parliamentary committee meeting. The draft sets fine ranges for individuals, officials, and legal entities, and introduces a separate fine for vaping in prohibited places and public areas.
Feb.27 by 2FIRSTS.ai
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
PMTA Roundtable Opens with Industry Questioning Product Characterization Standards, FDA Defends Regulatory Boundaries
At the opening of FDA’s PMTA roundtable, small ENDS manufacturers warned that unclear product characterization standards are limiting their ability to invest and raise capital. FDA officials acknowledged industry concerns but said regulatory flexibility is constrained by statutory and procedural boundaries.
Feb.11